الفهرس 
Diffuse Large B Cell LymphomaOnly 14 pages are availabe for public view
 |  | from | 201 |  |  |
| | | from | 201 | | |
Abstract
T
his study aimed to measure the serum level of 25 (OH)D in newly diagnosed DLBCL patients and correlate these levels with some prognostic parameters of the disease.
The study group included 30 newly diagnosed DLBCL patients, recruited from different heamatology/oncology units and 30 healthy controls of matched age and gender.
Median levels of serum vitamin D was found to be significantly lower in patients with DLBCL patients compared to control, which revealed a highly statistically significant difference (p value < 0.001).
Vitamin D level in patients with extra nodal involvement was significantly lower compared to patients without extra nodal involvement and was significantly lower in patients with bad performance status compared to patients with good performance status (ECOG\Zubrod).
We also found a significant inverse relationship between serum vitamin D level and serum LDH level, disease stage and serum Uric acid level.
We concluded that Serum 25 (OH) vitamin D deficiency is probably related to DLBCL aggressiveness and poor prognosis. So it could be considered as a potential prognostic marker of the disease. Whether normalizing vitamin D levels improves response to treatment and outcomes this warrants further clinical therapeutic trials.
We recommend measuring vitamin D level in all patients with DLBCL at presentation and after completing treatment, assessment of vitamin D in other types of lymphomas and lymphoproliferative diseases, Incorporation of vitamin D as an adjuvant treatment of DLBCL, assess the effect of normalization of its level on disease prognosis and conducting more studies with larger scales to confirm our findings.